Tabakerhitzer als neues Produkt der Tabakindustrie: Gesundheitliche Risiken

Pieper, Elke; Mallock, Nadja; Henkler-Stephani, Frank; Luch, Andreas

doi:10.1007/s00103-018-2823-y

Cited by 19 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A comparison of results is complicated by the heterogeneity of the HnB products studied and by the different measurement methods used [50]. Nevertheless, the overall picture that emerges from independent aerosol studies largely confirmed PMI’s findings, with respect to the levels of nicotine, carbon monoxide (CO), total particulate matter (TPM), and the main other HPHCs in the IQOS TM aerosol (e.g., volatile organic compounds, VOCs; aldehydes; polycyclic aromatic hydrocarbons; and tobacco-specific nitrosamines, TSNAs) [50,51,52,53,54,55,56,57,58]. Independent research with respect to (in vitro and in vivo) IQOS TM toxicology is rare (an exception being a study by Leigh and colleagues), whereas, human clinical and behavioral/experiential studies focusing on the IQOS TM use is virtually nonexistent [50,59].…”

Section: Introductionmentioning

confidence: 67%

IQOSTM vs. e-Cigarette vs. Tobacco Cigarette: A Direct Comparison of Short-Term Effects after Overnight-Abstinence

Adriaens

Gucht

Baeyens

2018

IJERPH

View full text Add to dashboard Cite

Introduction: Research from Philip Morris International’s science division on its Heat-not-Burn product IQOSTM focused on its chemical, toxicological, clinical, and behavioral aspects. Independent research on the experiences and behavioral aspects of using IQOSTM, and how it compares to e-cigarettes, is largely lacking. The current randomized, cross-over behavioral trial tried to bridge the latter gaps. Methods: Participants (n = 30) came to the lab on three consecutive days after being overnight smoking abstinent. During each session, participants used one of three products (cigarette, e-cigarette, or IQOSTM) for five minutes. Exhaled CO (eCO) measurements and questionnaires were repeatedly administered throughout the session. Results: Smoking a cigarette for five minutes resulted in a significant increase of eCO, whereas using an IQOSTM resulted in a small but reliable increase (0.3 ppm). Vaping did not affect eCO. Cigarette craving reduced significantly after product use, with the decline being stronger for smoking than for e-cigarettes or IQOSTM. Withdrawal symptoms declined immediately after smoking or using IQOSTM, and with some delay after vaping. IQOSTM scored higher in terms of subjective reward/satisfaction and was slightly preferred to the e-cigarette. Discussion: Short-term use of IQOSTM has a minimal impact on eCO, is equally effective in reducing cigarette craving and withdrawal symptoms as an e-cigarette, and is slightly preferred.

show abstract

Section: Introductionmentioning

confidence: 67%

IQOSTM vs. e-Cigarette vs. Tobacco Cigarette: A Direct Comparison of Short-Term Effects after Overnight-Abstinence

Adriaens

Gucht

Baeyens

2018

IJERPH

View full text Add to dashboard Cite

show abstract

“…Firstly, a significant reduction in toxicant concentrations was reported for the majority of the potentially reduced risk products. Depending on the product category, reduced exposure of up to 99% compared to CC was observed in product characterization studies by the manufacturers and reproduced by independent (governmental) organizations [ [19] , [20] , [21] , [22] , 24 , 52 ]. The decrease in toxicant exposure should be resembled in significantly reduced levels of the corresponding biomarkers of exposure compared to smokers of CCs [ 53 ].…”

Section: Methodsmentioning

confidence: 99%

“…Heated tobacco products (HTP) contain a tobacco substrate, designed to be heated and not combusted, to produce a nicotine-containing aerosol [ 18 ]. This new approach has been tested in studies organized by tobacco industry and independent governmental institutions, in first line indicating a reduced exposure to the harmful and potentially harmful chemicals [ [19] , [20] , [21] , [22] , [23] , [24] ].…”

Section: Introductionmentioning

confidence: 99%

Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial

Šibul

Burkhardt

Kachhadia

et al. 2021

Contemporary Clinical Trials Communications

View full text Add to dashboard Cite

Background Assessing biomarker profiles in various body fluids is of large value to discern between the sole use of nicotine products. In particular, the assessment of the product compliance is required for long-term clinical studies. The objective of this study was the identification of biomarkers and biomarker patterns in body fluids, to distinguish between combustibles, heated tobacco products, electronic cigarettes, oral tobacco and oral/dermal nicotine products used for nicotine replacement therapy (NRT), as well as a control group of non-users. Methods A controlled, single-center study was conducted with 60 healthy subjects, divided into 6 groups (5 nicotine product user groups and one non-user group) based on their sole use of the products of choice. The subjects were confined for 76 h, during which, free and uncontrolled use of the products was provided. Sample collections were performed according to the study time schedule provided in Table 2. The primary outcome will be validated through analysis of the collected biospecimens (urine, blood, saliva, exhaled breath and exhaled breath condensate) by means of untargeted omics approaches (i.e. exposomics, breathomics and adductomics). Secondary outcome will include established biomarker quantification methods to allow for the identification of typical biomarker patterns. Statistical analysis tools will be used to specifically discriminate different product use categories. Results/Conclusions The clinical trial was successfully completed in May 2020, resulting in sample management and preparations for the quantitative and qualitative analyses. This work will serve as a solid basis to discern between biomarker profiles of different nicotine product user groups. The knowledge collected during this research will be required to develop prototype diagnostic tools that can reliably assess the differences and evaluate possible health risks of various nicotine products.

show abstract

“…To address the individual risk reduction associated with THS use, premarket assessment studies including aerosol chemistry, in vitro and in vivo toxicity studies, and clinical studies coherently demonstrate that switching from cigarette smoking to THS use consistently and significantly reduces the exposure to harmful and potentially harmful constituents (HPHCs) to levels that approach the reductions associated with smoking abstinence [7-15]. Numerous independent studies [16-19] and government-affiliated labs including the FDA’s Southeast Tobacco Laboratory [20], UK Committee on Toxicity [21], German Federal Institute for Risk Assessment (BfR) [22], Japan National Institute of Public Health [23], New Zeeland CRL Energy Ltd [24], and Dutch National Institute for Public Health and Environment (RIVM: Rijksinstituut voor Volksgezondheid en Milieu ) [25] have evaluated the aerosol chemistry of THS and confirmed the lower levels of HPHCs in the emissions of THS. Public Health of England [26] has systematically reviewed the existing evidence on THS and concluded that THS is likely to expose users to lower levels of HPHCs.…”

Section: Introductionmentioning

confidence: 99%

Household Surveys in the General Population and Web-Based Surveys in IQOS Users Registered at the Philip Morris International IQOS User Database: Protocols on the Use of Tobacco- and Nicotine-Containing Products in Germany, Italy, and the United Kingdom (Greater London), 2018-2020

Sponsiello-Wang¹,

Langer²,

Prieto³

et al. 2019

JMIR Res Protoc

View full text Add to dashboard Cite

Background Philip Morris International (PMI) has developed a novel heat-not-burn tobacco product, Tobacco Heating System (THS), which is marketed under the brand name of IQOS with HEETS (IQOS). The aerosol generated by THS has substantially fewer toxicants than combustible cigarette smoke, although the extent of the reduction of harmful and potentially harmful constituents reported varies between studies. To evaluate the potential harm reduction associated with IQOS use, the assessment of the uptake and continued use of IQOS in the context of all other tobacco- and nicotine-containing products is crucial. In March 2018, PMI launched cross-sectional surveys in Germany, Italy, and the United Kingdom (Greater London) to estimate the prevalence and use patterns of IQOS and other tobacco- and nicotine-containing products use in these 3 markets following the commercialization of IQOS. This study describes the protocol of the surveys. Objective The objectives of these surveys are to estimate the prevalence of tobacco- and nicotine-containing products use; describe past and current patterns of use; and explore their associations with self-reported health, motivation to use, risk perceptions, and perceived aesthetic changes. Methods The overall design of the surveys is similar in all 3 countries. Repeated cross-sectional surveys are being conducted annually over 3 consecutive years (2018 to 2020) and in 2 samples: a representative sample of the general population and a sample of IQOS users. A total of 6085 adults per year will be selected from the general population for each survey through multistage stratified sampling, and participants will respond to face-to-face computer-assisted personal interviews. In addition, 1404, 1384, and 1246 IQOS users per year in Germany, Italy, and Greater London, respectively, will be randomly selected from the PMI IQOS user database and will be invited to complete the Web-based survey using computer-assisted self-interviews. The Smoking Questionnaire is used to assess the tobacco use patterns of the participants. Results The recruitment of the general population sample began in March 2018 and that of the IQOS user sample began in April 2018. The data collection is ongoing, and the results of the first year data analysis are expected to be available by June 2019. Conclusions As the design of the 3 surveys is similar, the results will allow for cross-countries comparison of the prevalence of IQOS and other tobacco- and nicotine-containing products use as well as patterns of use and associated factors. International Registered Report Identifier (IRRID) DERR1-10.2196/12061

show abstract

Tabakerhitzer als neues Produkt der Tabakindustrie: Gesundheitliche Risiken

Cited by 19 publications

References 31 publications

IQOSTM vs. e-Cigarette vs. Tobacco Cigarette: A Direct Comparison of Short-Term Effects after Overnight-Abstinence

IQOSTM vs. e-Cigarette vs. Tobacco Cigarette: A Direct Comparison of Short-Term Effects after Overnight-Abstinence

Identification of biomarkers specific to five different nicotine product user groups: Study protocol of a controlled clinical trial

Household Surveys in the General Population and Web-Based Surveys in IQOS Users Registered at the Philip Morris International IQOS User Database: Protocols on the Use of Tobacco- and Nicotine-Containing Products in Germany, Italy, and the United Kingdom (Greater London), 2018-2020

Contact Info

Product

Resources

About